Neox Clinical Research Opens its First US Office in San Diego
Neox Clinical Research, a Czech-based CRO, is pleased to announce they will be opening an office in San Diego, California in the first quarter of 2012 as their North American headquarters.
"Opening an office in the United States is a natural geographic addition for our overall global growth strategy. As we continue to add clients, backlog, feature sets and staff in the US it was an easy choice for us to open an office in San Diego," said Pavel Marek MD, CEO, Neox.
Heading up the US operations is Matt Delaney, Managing Director, Neox US Matt is an industry executive with more than 25 years of experience. Matt was previously Vice President of worldwide sales and marketing for a mid-size global CRO. "We are delighted to have Matt join the Neox team. Matt's experience in building and managing regions and teams will be a key ingredient for Neox's overall success", said Pavel Marek.
Neox also strengthens its management team in Europe. Jennifer Haggard, MS, has been hired to act as the Managing Director of Neox Europe. She is strategically located in a newly opened Neox office in Aachen, Germany. Jen has a long-lasting experience from both CRO and Pharma industries. "I believe that Jen is the key person for the overall management of European operations", said Pavel Marek. "I am delighted to be a part of the Neox team. Our experience conducting trials in CEE countries is significant and further expansion throughout Europe is paramount for Neox," Jen stated.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
